GS-5894 / Gilead - LARVOL DELTA

Improving transparency on patenting strategies of HIV medicines candidates to anticipate access challenges (AIDS 2026) - " Based on monitoring of clinical trials for new HIV antiretrovirals (ARVs), the following compounds were selected: GS-1614; GS-6212; GS-5894; GS-4182; GS-1720, VH4011499; VH4004280; VH4367310; VH-310; VH4524184; MK-8527; MK-850, islatravir... The findings have shown the multiple patenting on key antiretrovirals – reflecting the evergreening strategy - and an initial patent filing for newer compounds, allowing national-level monitoring by MMA members, and anticipating patent applications to be challenged. However, the lack of transparency of chemical structures has hindered the ability to develop an accurate patent landscape, which is an access challenges to promising candidates in the drug pipeline."

Human Immunodeficiency Virus • Infectious Disease

Study of Novel Antiretrovirals in Participants With HIV-1 (clinicaltrials.gov) - P1 | N=49 | Completed | Sponsor: Gilead Sciences | Active, not recruiting ➔ Completed | Trial completion date: Mar 2027 ➔ Mar 2024 | Trial primary completion date: Mar 2027 ➔ Mar 2024

Trial completion • Trial completion date • Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease • CD4

Study of Novel Antiretrovirals in Participants With HIV-1 (clinicaltrials.gov) - P1 | N=49 | Active, not recruiting | Sponsor: Gilead Sciences | Recruiting ➔ Active, not recruiting | N=110 ➔ 49 | Trial completion date: Dec 2024 ➔ Mar 2027 | Trial primary completion date: Dec 2024 ➔ Mar 2027

Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease • CD4

Study of Novel Antiretrovirals in Participants With HIV-1 (clinicaltrials.gov) - P1 | N=110 | Recruiting | Sponsor: Gilead Sciences | Trial completion date: May 2024 ➔ Dec 2024 | Trial primary completion date: May 2024 ➔ Dec 2024

Trial completion date • Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease • CD4

Preclinical Characterization of GS-5894, a Potent NNRTI With Once-Weekly Oral Dosing Potential (CROI 2024) - "GS-5894 is a novel and potent NNRTI with an improved resistance profile compared to other NNRTIs. Given the high plasma binding and low predicted metabolic clearance, GS-5894 has the potential for once-weekly oral dosing in PWH for the treatment of HIV-1 infection."

Preclinical • Human Immunodeficiency Virus • Infectious Disease • CD4

Study of Novel Antiretrovirals in Participants With HIV-1 (clinicaltrials.gov) - P1 | N=110 | Recruiting | Sponsor: Gilead Sciences | Phase classification: P1b ➔ P1

Phase classification • Human Immunodeficiency Virus • Infectious Disease • CD4

Study of Novel Antiretrovirals in Participants With HIV-1 (clinicaltrials.gov) - P1b | N=110 | Recruiting | Sponsor: Gilead Sciences | Not yet recruiting ➔ Recruiting

Enrollment open • Human Immunodeficiency Virus • Infectious Disease • CD4

Study of Novel Antiretrovirals in Participants With HIV-1 (clinicaltrials.gov) - P1b | N=110 | Not yet recruiting | Sponsor: Gilead Sciences

New P1 trial • Human Immunodeficiency Virus • Infectious Disease • CD4